Siegismund CS, et al. - Among patients with cardiac transthyretin amyloid (ATTR) or amyloid light-chain (AL) amyloidosis, researchers assessed the impact of endomyocardial biopsy (EMB)-proven intramyocardial inflammation on mortality. For the first time, a high incidence (48.1%) of intramyocardial inflammation was reported in a series of patients with EMB-proven cardiac amyloidosis, and in patients with AL amyloidosis, intramyocardial inflammation was noted to have a significant correlation with increased mortality. The data seem to imply that, in patients with biopsy-proven inflammation of heart muscle tissue, additional immunomodulating/anti-inflammatory treatment regimens could be beneficial for patients suffering from cardiac AL amyloidosis.